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Abstract  
Waardenburg syndrome (WS) is an auditory-pigmentary disorder that exhibits varying 
combinations of sensorineural hearing loss and abnormal pigmentation of the hair and skin. 
Depending on additional symptoms, WS is classified into four subtypes, WS1 to 4. Absence 
of additional features characterizes WS2. The association of facial dysmorphic features 
defines WS1 and 3 whereas the association with Hirschsprung disease (aganglionic 
megacolon) characterizes WS4, also called Waardenburg-Hirschsprung disease. Mutations 
within the genes encoding MITF and SNAI2 have been identified in WS2, whereas mutations 
of EDN3, EDNRB and SOX10 have been observed in WS4 patients. However, not all cases 
are explained at the molecular level, raising the possibility that other genes are involved or 
that some mutations within the known genes are not detected by commonly used genotyping 
methods. We used a combination of semi-quantitative fluorescent multiplex PCR (QMF-
PCR) and Fluorescent in situ hybridization (FISH) to search for SOX10 heterozygous 
deletions. We describe the first characterization of SOX10 deletions in patients presenting 
with WS4. We also found SOX10 deletions in WS2 cases, making SOX10 a new gene of 
WS2. Interestingly, neurological phenotypes reminiscent of that observed in WS4 (PCWH 
syndrome) were observed in some WS2 patients with SOX10 deletions. This study further 
characterizes the molecular complexity and the close relationship that links the different 
subtypes of Waardenburg syndrome. 
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Introduction 
During development, the pluripotent neural crest cells migrate from the neural tube 
throughout the embryo along several pathways and give rise to different cell types, including 
glia and neurons of the peripheral nervous system, enteric neurons and glia, some of the 
craniofacial skeletal tissue and melanocytes of the skin and inner ear 
1
. Defects in neural crest 
development are a significant cause of human disease. The term neurocristopathies 
collectively refers to these neural crest disorders, among which is Waardenburg syndrome 
(WS) 
2-4
. The association of hearing loss and pigmentary abnormalities (heterochromia irides, 
white skin patches, white forelock…) characteristic of this syndrome results from an 
abnormal proliferation, survival, migration or differentiation of neural crest-derived 
melanocytes 
3
. Several subtypes of WS were defined on the basis of the presence of 
additional symptoms. 
Type I Waardenburg syndrome (WS1, MIM_193500) refers to the first cases 
described by Waardenburg 
5
. Additional symptoms are dystopia canthorum and broad nasal 
root. Nearly all patients present with heterozygous PAX3 mutations (PAX3, paired box gene 
3, a member of the paired box family of transcription factor). Type III Waardenburg 
syndrome (WS3, MIM_148820) or Klein-Waardenburg syndrome, is an extreme presentation 
of type I with hypoplasia of limb muscles and is also due to heterozygous or homozygous 
mutations of PAX3 
6; 7; 3
. 
Type II Waardenburg syndrome (WS2, MIM_193510) is characterized by deafness 
and pigmentation defects without additional features. Heterozygous mutations in the MITF 
gene (MITF, microphthalmia associated transcription factor, a basic-helix-loop-helix 
transcription factor) have been identified in about 15% of cases 
8; 3
. Homozygous deletions of 
the SNAI2 gene (Snail homolog 2, a C2H2-type zinc finger transcription factor) have also 
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been described in two patients 
9
. Therefore, 85% of WS2 cases are still unexplained at the 
molecular level. 
Type IV Waardenburg syndrome (WS4, MIM_277580), also called Shah-
Waardenburg syndrome or Waardenburg-Hirschsprung disease, combines pigmentation 
defects, deafness and Hirschsprung disease 
10
. Mutations in EDNRB, encoding the endothelin 
B receptor (a G-protein coupled transmembrane receptor), and EDN3, encoding its ligand 
endothelin-3, have been described. Homozygous (most frequently) or heterozygous mutations 
are found in WS4 probands, while heterozygous family members occasionally present with 
some of the features 
11-14; 4; 15-17
. 
Dominant mutations of SOX10 have also been identified in WS4 
18
. SOX10 is a key 
transcription factor of neural crest development. It is crucial for the survival and maintenance 
of pluripotency of migrating neural crest progenitors 
19; 20
, and also influences fate decisions 
and differentiation at later stages 
21-25
. SOX10 belongs to the SOX family of transcription 
factors and is closely related to SOX8 and SOX9, the latter being involved in campomelic 
dysplasia 
26; 27; 21; 23; 25
. All SOX proteins contain a DNA binding motif known as the high-
mobility group (HMG) domain. In addition, SOX10, like SOX8 and SOX9, contains a 
transactivation domain located in the C-terminal part of the protein and a dimerization 
domain immediately preceding the HMG domain 
21; 28; 29; 22
. Functional studies revealed the 
importance of these domains for monomeric or dimeric DNA binding and transactivation of 
natural target genes 
21; 22
. Among them are genes/factors crucial for the specification and 
differentiation of melanocytes or enteric nervous system development, such as MITF/Mitf, 
TRYP2/Dct (Dopachrome tautomerase), tyrosinase, EDNRB, and the RET protooncogene 
30-
41
. SOX10 targets also include genes important for glia development and identity such as 
MPZ (Myelin protein zero, P0), MBP (Myelin basic protein), and GJB1 (encoding the gap 
junction protein connexin 32) 
29; 42-46
. 
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The SOX10 mutations characterized so far are mostly truncating mutations: nonsense 
or frameshift and one splice mutation, which most often remove all or part of the 
transactivation domain 
18; 47-58
. An insertion of two amino acids and an amino acid 
substitution in the HMG domain, as well as two mutations of the stop codon supposed to give 
rise to elongated SOX10 protein, have also been described 
18; 48; 49; 53
. Unexpectedly, some of 
the patients with SOX10 mutations present with chronic intestinal pseudo-obstruction instead 
of Hirschsprung disease 
51; 55
, and/or neurological features, either peripheral demyelinating 
neuropathy or central neuropathy, or both, leading to a syndrome called PCWH (Peripheral 
demyelinating neuropathy-Central dysmyelinating leukodystrophy-Waardenburg syndrome-
Hirschsprung disease) 
57
. This more severe disease is mostly due to mutations in the last 
coding exon of SOX10 and has been proposed to occur when the mutant mRNAs escape the 
non-sense RNA decay (NMD) pathway 
57
. 
However, some WS4 cases remain unexplained at the molecular level, suggesting that 
other genes may be involved, or that some mutations within the known genes are not detected 
by the methods commonly used for genotyping. Therefore, we used semi-quantitative 
fluorescent multiplex PCR (QMF-PCR) to search for heterozygous SOX10 deletions. Here we 
describe the first characterization of SOX10 deletions in patients presenting with WS4. In 
light of the phenotypic variability observed among patients with SOX10 point mutations, we 
also searched for SOX10 deletions in unexplained cases of WS2 and found several, making 
SOX10 a new gene of WS2. 
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Subjects and methods 
Subjects 
We investigated a total of 30 patients presenting with the classic form of WS4 or PCWH: 29 
of them negative for EDN3, EDNRB and SOX10 point mutations, and one found hemizygote 
for a SOX10 point variation within the course of this work. Our study also included 30 WS2 
patients without MITF mutations. Clinical information and DNA samples were obtained with 
informed consent according to French law for genetic testing. The main clinical findings in 
patients presenting with SOX10 gene deletions are summarized in Table 4. Detailed clinical 
descriptions of the patients presenting with SOX10 gene deletions are as follows: 
Patient 1, a one-year-old male, was born at term of unrelated parents after unremarkable 
pregnancy and delivery. At 48 hours of life he presented with clinical signs of meconium 
plug syndrome due to a short-segment Hirschsprung disease. Bilateral absence of responses 
to brainstem auditory-evoked potential strongly suggested bilateral deafness. He also had hair 
and skin hypopigmentation and bilateral cryptorchidism. 
Patient 2, a 13-year-old male, was born at term of unrelated parents, following a pregnancy 
complicated by gestational diabetes. He has two healthy sisters. He had delayed psychomotor 
development, hair and skin hypopigmentation, sapphire blue eyes and short-segment 
Hirschsprung disease operated at the age of 15 months. Nine months later, he had 
implementation of a unilateral cochlear device for profound bilateral congenital deafness. In 
spite of good perceptual results, he had speech and sign language impairment because of 
dyspraxia. He had mild mental retardation, anosmia, hypermetropia and dental enamel 
abnormalities.  
Patient 3 is a 36 year-old male, born at term of unrelated parents after unremarkable 
pregnancy and delivery. In the neonatal period, he had axial hypotonia and delayed 
psychomotor development: he could hold his head up at 1 year, sit alone at 3 years and walk 
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at 4-5 years. He had hair and skin hypopigmentation, sapphire blue eyes, short-segment 
Hirschsprung disease and profound bilateral congenital deafness for which he had 
implementation of a unilateral cochlear device at the age of 32 years. Temporal bone CT scan 
revealed a bilateral vestibular malformation and hypoplasia of the external and posterior 
semicircular canals. He also presented anosmia, bilateral cryptorchidism and 
hypogonadotropic, hypogonadism, bone-age and pubertal growth delay. He now has mild 
mental retardation with marked abstraction difficulties. 
Patient 4, a 9-year-old male, was born at term of unrelated parents after unremarkable 
pregnancy and delivery. He began to walk at 21 months of age. A bilateral sensorineural 
hearing impairment was discovered at 6 months of age and progressed to profound deafness. 
A cochlear implantation was performed with success in terms of understanding and of 
language. Temporal bone CT scan revealed a symmetrical bilateral vestibular malformation 
with dilatation of the vestibule, hypoplasia and dilatation of the external and posterior 
semicircular canals. He presented skin, irides and retina hypopigmentation. He had no history 
of constipation and his neurological development was normal. His brother presented with 
similar clinical symptoms. No other cases of hearing defect or pigmentation anomalies were 
observed in the family.  
Patient 5 a 8-year-old male, was born at term of unrelated parents after unremarkable 
pregnancy and delivery. He began to walk at 20 months of age. A profound bilateral 
sensorineural hearing impairment was diagnosed at 5 months of age. Temporal bone CT scan 
did not reveal any malformation of the inner ears. He presented with skin depigmentation and 
hypoplastic irides. He had no history of constipation and his neurological development was 
normal. His mother presented a bilateral severe sensorineural prelingual hearing impairment. 
She was born with a frontal white forelock and a heterochromia (one green iris, one 
hypoplastic). 
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Patient 6, now aged 8, is the third child of a non-consanguineous couple from the French 
Caribbean Islands. At 9 months of age, a severe bilateral sensorineural hearing impairment 
was diagnosed, and progressed to a bilateral profound deafness by 8 years of age. He 
presented a white frontal forelock at birth and heterochromia irides (one black and one 
hypoplastic) but has no skin depigmentation. He began walking at 17 months of age and has 
no history of severe constipation or neurological anomaly. 
Patient 7, now aged 23, was born at term of unrelated parents after unremarkable pregnancy 
and delivery. He presented with a white frontal forelock (now disappeared), skin 
hypopigmentation, sapphire blue eyes, pectus excavatum and statural growth following the 
3rd percentile. He has no constipation problems. In addition this patient has severe autism 
and developmental delay (he started to walk at 3 years, is not toilet-trained and has little 
autonomy). Brain CT scan was normal. Bilateral sensorineural deafness was diagnosed at the 
age of 9 months and he had cochlear implementation up to the age of 13 years. However, due 
to severe behavioral problems, hearing loss has not been evaluated since. 
Patient 8 was born at term of unrelated parents after unremarkable pregnancy and delivery. 
She presented with severe congenital heart disease associating double outlet right ventricle, 
transposition of the great arteries, pulmonary atresia, patent ductus arteriosus, ventricular 
septal defect and atrial septal defect. A white forelock and a duplication of the thumb on the 
left side were noted. At age10 months, she presented obvious evidence of deafness, medial 
flare of the eyebrows, strabismus and general hypotonia. Brain MRI scan at age 14 months 
showed delayed myelination. Specific evaluation of the skin on Wood's lamp revealed 
multiple hypopigmented areas. She had no history of constipation. Heart surgery had been 
partially successful but episodes of unexplained bradychardia and peripheral cyanosis were 
observed and the patient died at the age of 19 months. 
Semi quantitative fluorescent multiplex PCR (QMF-PCR) 
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QMF-PCR has been shown to be a sensitive method for the detection of gene dosage 
anomalies, and has been successfully used in our laboratory to characterize deletions and 
duplications within several genes 
59; 60
. We adapted the protocol previously described 
61; 59
 to 
screen for SOX10 gene deletions. Briefly, the 3 coding exons of the SOX10 gene, exon 4 of 
POLR2F and 4 regions located 5‟ of SOX10 were amplified in two multiplex reactions. The 
beginning of exon 3 and the middle of the exon 5 coding sequences are not covered by the 
amplicons, however a deletion restricted to one of these region would have been found during 
the point mutation screening. Non-coding regions of SOX10 were not studied. GenBank 
accession number, position, sequences of the primers, and PCR product sizes are shown in 
Table 1. In each set, two controls were used: DSCR1 located on chromosome 21 and F9 
located on chromosome X (see reference genes in Table 1). The reverse primers were 
labelled with the fluorescent phosphoramidite 6-FAM dye. Amplifications were performed in 
duplicates in 25l reactions using the QIAGEN Multiplex PCR kit (Qiagen, France), with 75 
ng of genomic DNA, a mix of primers (concentration range 0.1 to 1 M), and 5% DMSO. 
The reaction started with an initial denaturation of 15 min at 95°C followed by 22 cycles at 
95°C for 30 sec, 55°C (multiplex reaction mix 1) or 58°C (multiplex reaction mix 2) for 30 
sec, and 72°C for 45 sec with an increment of 3 sec per cycle, and a final extension of 10 min 
at 72°C. Then, 3l of the purified PCR products were processed as previously described 59. 
Two control DNAs (male and female) were included in each experiment. Results were 
analysed by superimposing fluorescent profiles of tested patients and controls and by 
calculating dosage quotient (DQ) 
59
. DQ values below 0.6 were considered as potential 
deletions. Table 2 summarizes examples of DQ values obtained. 
Molecular characterization of rearrangements 
When QMF-PCR revealed a short size deletion (only one exon removed), the genomic region 
encompassing the deletion breakpoint was amplified either by classic or long range PCR 
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using Dynazyme Ext DNA polymerase (Ozyme, France) or the Expand Long Template PCR 
system (Roche Diagnosis, France), respectively. The resulting PCR fragments were cloned 
into the TOPO-TA cloning kit Dual promoter or the TOPO-XL PCR cloning kit (Invitrogen, 
France) and sequenced. Bioinformatic analysis was performed to predict the functional 
consequences of intragenic deletions using Netgene2 (neural network predictions of splice 
sites in human) and HMMgene (gene prediction structure) softwares. 
In the case of whole SOX10 gene deletions, fluorescent in situ hybridization (FISH) was used 
to confirm the QMF-PCR results. Molecular cytogenetic studies were performed on 
chromosomes prepared from cultured fibroblasts (patient 8) or peripheral blood cells. 
Metaphase chromosomes were obtained according to standard techniques. FISH was 
performed as previously described 
62
. PAC and BAC clones used in FISH experiments were 
provided by the BACPAC Resources Center, (CHILDREN'S HOSPITAL OAKLAND, 
Oakland, USA) or by The Wellcome Trust Sanger Institute (Cambridge, UK). Clones 
localized on chromosome 22q12-q13.2 (CTA-415G2, LL22NCO1-95B1, RP1-288L1, CTA-
714B7, RP1-41P2, CTA-390B3, RP5-1177I5, RP1-37E16, RP3-466N1, RP5-1014D13, RP5-
1039K5, CTA-228A9, CTA-447C4, RP1-5O6, RP3-434P1, RP1-319F24, RP3-508I1S, RP3-
327516, CTA-150C2, RP4, 742C19, LL22NC03-10C3) were directly labelled with Cy3. The 
control probes (RP1-41P2 and RP1127L4) were directly labelled with FITC, and 
chromosomes were counterstained with Dapi. The specific signal intensity and its 
sublocalization along the chromosome axis were analysed using a Leica fluorescence 
microscope equipped with the Visilog-6 program (Noesis, Les Ulis, France). Based on FISH 
results, additional QMF-PCR primers were designed to delineate the extent of deletions. 
Position and sequences of these additional primers are reported in Table 3. 
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Chromosome segregation analysis 
Seven chromosome 22 microsatellites (D22S420; D22S539; D22S315; D22S280; D22S283; 
D22S423; D22S274) were analysed in patient 3 and his parents using the linkage mapping set 
(Applied Biosystem, USA) according to the manufacturer‟s instructions. 
SOX10 point mutation screening in WS2 patients 
In the absence of a full description of the 5‟UTR non-coding exon(s) of SOX10, we 
conserved for convenience the exon numbering system previously used, i.e. non-coding 
exons 1 and 2, ATG codon in exon 3 and stop codon in exon 5 
18
. Three sets of primers were 
used to amplify the SOX10 gene fragments covering coding exons 3 to 5 and intron-exons 
boundaries (First set: exon 3, 5‟-ACCCACCTAGAGTCTGGCATG-3‟ and 5‟- 
CTCGGCTACCCTGAATCCAC-3‟, size of PCR product 733 bp; second set: exon 4, 5‟-
CCACAAATCATAGGGCACAG-3‟ and 5‟-TAGAGTCCAGGGTCTCATTG-3‟, size of 
PCR product 523 bp; third set: exon 5, 5‟-CCTGCCTCTAACCTGCTTCC-3‟ and 5‟-
ACCTCCTTCTCCTCTGTCCA-3‟, size of PCR product 997 bp). The PCR covering the 
exon 3 region contained 10% DMSO. Resulting PCR products were sequenced using a 16 
capillary ABI Prism sequencer and the Terminator Cycle Sequencing kit. Additional internal 
sequencing primers were used for exon 3: 5‟- GCGAGCTGGGCAAGGTCAAG-3‟ and 5‟-
TCGCCGTCCTGCTGCTCCTT-3‟ and exon 5: 5‟-GGATGCCAAAGCCCAGGTGA-3‟ and 
5‟-GTAGGCGATCTGTGAGGTGG-3‟. 
Plasmids, cell culture, transfection and reporter assays 
The pECE-SOX10, pECE-SOX10-E189X, pECE-SOX10-Y313X, pECE-SOX10-482ins6, 
pECE-PAX3, pECE-EGR2, pGL3-MITFdel1718, pGL3-Cx32 vectors were previously 
described 
30; 43
. The p.Val92Leu mutation (named V92L for convenience) was introduced 
within the pECE-SOX10 construct by site directed mutagenesis using the Quick change 
mutagenesis kit (Stratagene, Netherlands). Luciferase assays and immunofluorescence were 
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performed 24h after transfection of HeLa cells as previously described 
30; 43; 63
. The SOX10 
antibody used for immunofluorescence was previously described 
64
. The P0 construct was 
kindly provided by M. Wegner 
29
. 
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Results 
Identification of SOX10 deletions in patients presenting with WS4 or PCWH 
In our experience, about 20-40% of affected individuals with the WS4 or PCWH phenotypes 
have no mutations within SOX10, EDN3 or EDNRB genes identifiable by conventional 
genetic analysis using DNA sequencing of PCR-amplified gene segments. As this technique 
does not detect heterozygous deletions, we decided to search for SOX10 deletions or 
rearrangements by semi-quantitative fluorescent multiplex PCR (QMF-PCR). Our study 
included 29 patients presenting with the classic form of WS4 or PCWH previously found 
negative for SOX10, EDN3 and EDNRB point mutations. We first analyzed the 3 coding 
exons of SOX10, part of the POLR2F downstream gene, and sequences located up to 50 kb 
upstream of SOX10 (S1 to S4, see Fig.1A). One of them, S1, was previously described as a 
SOX10 enhancer 
65
 (see Table 1 for sequences of primers named P1 to P9). 
We identified two heterozygous deletions (Patients 1 and 2; see case reports and Table 4 for 
clinical descriptions). The first, found in a patient presenting with a classical WS4 phenotype, 
removes part of exon 5 (Fig.1A, patient 1). PCR amplification using primers located in intron 
4 and exon 5, cloning and sequencing of the resulting products revealed a complex 
rearrangement combining a 1128 bp deletion encompassing 740 bp of the fourth intron and 
388 bp of exon 5, and a 3 bp insertion (Fig.1B). The other deletion, found in a PCWH patient, 
includes the whole SOX10 gene, POLR2F and the upstream S4 sequence (Fig.1A, patient 2). 
FISH analysis using a BAC encompassing the whole region (clone RP5-1039K5, Fig.1A) 
confirmed the QMF-PCR results. Indeed, we observed a significantly decreased signal on one 
of the chromosomes 22 in all the metaphases (Fig 1C, patient 2), showing that the deletion 
only removes part of the RP5-1039K5 probe (S1 to S3 are not deleted, see Fig.1A). In each of 
the 2 cases, the analysis of parents DNA by QMF-PCR revealed the de novo occurrence of 
the deletion (Table 4). 
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Detection of a SOX10 deletion in a PCWH patient with p.Val92Leu variation 
Sequencing of the SOX10 coding exons and intron-exon boundaries in newly recruited 
patients led us to identify a new point mutation (nucleotide substitution c. 274G>C in exon 3) 
that predicts the replacement of a Valine by a Leucine at codon 92 (p.Val92Leu) in a patient 
presenting with PCWH (patient 3; see case report and Table 4 for clinical description). This 
amino acid substitution affects a residue located within a region directly preceding the HMG 
domain that is not only well conserved between SOX10 proteins across evolution, but also 
with the SOX E members, SOX8 and 9 (Fig.2A) 
28
. Surprisingly, this variation was observed 
at the homozygous state, and therefore contrasts with the heterozygous state of all the 
mutations identified to date. The parents were not consanguineous nor presented any feature 
of the disease, except for early greying in the mother. We found the mutation at the 
heterozygous state in the father‟s DNA only. The analysis of seven chromosome 22 
microsatellites excluded a chromosome segregation abnormality and the possibility of a 
chromosome 22 paternal isodisomy (data not shown). 
To explain these data, we searched for a deletion or rearrangement of SOX10 that would 
result in a hemizygous p.Val92Leu mutation. QMF-PCR experiments indeed unravelled a 
deletion that removes the whole SOX10 gene, along with the upstream and downstream 
sequences tested (Fig.1A, patient 3). FISH analysis using the BAC clone RP5-1039K5 
confirmed the presence of a deletion encompassing the whole region (Fig.1C, patient 3, 
presence of only one signal on the normal chromosome 22). Analysis of parents‟ samples 
established the de novo occurrence of the deletion (Table 4). 
These results suggested that the phenotype of patient 3 is related to this large deletion, but we 
could not exclude that the p.Val92Leu variation contributes to the phenotype. To test this 
possibility, we introduced the mutation into the SOX10 cDNA and analysed its functional 
consequences in vitro. Immunofluorescence experiments on HeLa cells transiently 
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transfected with wild type or p.Val92Leu constructs revealed correct nuclear localization of 
the mutant protein (Fig.2B). 
The region affected by the mutation was previously implicated in DNA dependent 
dimerization, both in SOX10 and SOX9 
29; 42; 45; 66
. Moreover, a SOX9 mutation located in the 
same region (p.Ala76Glu) was shown to selectively abrogate DNA-dependent dimerization 
and thus interfere with promoter activation via natural target sites that require binding of 
SOX9 as dimers 
66
. We therefore analysed the transactivation potential of the p.Val92Leu 
mutant on two promoters previously shown to contain monomeric or dimeric SOX10 binding 
sites, respectively MITF and Cx32. Indeed, SOX10, in synergy with PAX3, regulates MITF 
expression by directly binding to its promoter as monomers 
30; 33
. SOX10, on the other hand, 
regulates GJB1 (encoding connexin 32, Cx32) expression by directly binding to its promoter 
on a dimeric configuration and in synergy with its cofactor EGR2 
43; 67
 (insets in Fig.2C and 
D). Cotransfection of either promoter with wild type or p.Val92Leu SOX10 mutant, and/or 
SOX10 cofactors (PAX3 and EGR2), revealed that normal and mutant SOX10 have similar 
transactivation capacities on these promoters, alone or in synergy with the cofactors (Fig.2C 
and D). In contrast, three previously identified SOX10 mutations (p.Glu189X, c.482ins6, and 
p.Tyr313X, respectively named E189X, 482ins6 and Y313X in fig 2C and D) failed to 
transactivate these reporter constructs, as previously described 
30; 43; 68
. We also performed 
similar experiments using another SOX10-responsive promoter known to contain SOX10 
dimeric binding sites, P0, and found no difference between wild type and p.Val92Leu mutant 
transactivation capacities (data not shown). Therefore, the p.Val92Leu variation does not 
seem to affect SOX10 function, at least in vitro, arguing in favour of the deletion as the cause 
of the phenotype observed in this patient. 
Molecular characterization of large deletions in PCWH patients 
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To define the boundaries of the deletions encompassing the SOX10 gene found in patients 2 
and 3, we extended our analysis to adjacent regions using two complementary strategies: 
FISH and QMF-PCR. 
In case of patient 2, we chose additional sets of QMF-PCR primers localised between 
upstream S3 and S4 sequences, allowing us to map the telomeric border of the deletion to a 
region located 24 to 31 kb upstream of the SOX10 start codon (Fig.3B, patient 2). In parallel, 
FISH experiments with the probe RP5-1014D13 (covering regions proximal to POLR2F, 
including MICAL-L1 gene, see Fig.3), showed a distinct signal on both chromosomes 22, 
positioning the centromeric border of the deletion between POLR2F and MICAL-L1 genes 
(Fig.3A). We chose additional sets of QMF-PCR primers within the genes located in the 
region and localized the end of the deletion between exons 3 and 4 of the C22ORF23 
sequence (Fig.3B and Table 3 for corresponding primers). The whole deletion therefore 
encompasses 56 to 68 kb including, in addition to SOX10, POLR2F and part of C22ORF23 
genes. 
In the case of patient 3, we carried out FISH analysis using RP5-1014D13 on one side, and 
CTA-228A9 on the other. This allowed us to localize the centromeric border of the deletion 
between RP5-1014D13 (that shows hybridization on both chromosomes 22) and RP5-
1039K5 (that shows only one signal on normal chromosome 22) (Fig.3A and Fig.1C). The 
telomeric border was localized within the CTA-228A9 (we observed a significantly 
decreased signal on one of the chromosomes 22 in all the metaphases, Fig.3A). Based on 
these results, we repeated a series of multiplex PCR using primers located within C22ORF23 
or MICAL-L1 genes on one side and in the PLA2G6 gene on the other, and could finally 
determine the deletion boundaries between intron 9 and exon 8 of the MICAL-L1 gene and 
between exon 4 and intron 2 of the PLA2G6 gene (Fig.3B and Table 3 for corresponding 
primers). The whole deletion therefore encompasses 213 to 222 kb, including part of MICAL-
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L1 gene, C22ORF23, POLR2F, SOX10, PICK1, SLC16A8, BAIAP2L2 genes, and part of the 
PLA2G6 gene. 
Identification of SOX10 deletions in WS2 patients 
WS4 patients with SOX10 point mutations or deletions exhibit a large variability and an 
incomplete penetrance of each feature (ie, fully blue irides, patchy blue irides or normal eyes; 
large, small or none depigmented skin patches; short or long segment Hirschsprung disease or 
chronic intestinal pseudo-obstruction…). Interestingly, we previously described a 
c.1076delGA mutation in a patient with a classical form of WS4 
18
, that was inherited from a 
mother presenting with deafness and white forelock only. We also described a p.Ser135Thr 
(S135T) mutation in a patient presenting with a peculiar phenotype named “Yemenite deaf-
blind hypopigmentation syndrome” without any intestinal dysfunction 48. These two 
phenotypes, which are reminiscent of that observed in WS2 patients, prompted us to search 
for SOX10 deletions in unexplained cases of WS2. Screening of 30 cases (previously found 
negative for MITF) by means of QMF-PCR allowed us to identify 5 different SOX10 
deletions (patients 4 to 8; see case report and Table 4 for clinical descriptions). 
The first encompasses exon 3 (Fig.4A, patient 4). PCR amplification using sets of primers 
located in exon 3 and intron 3, followed by cloning and sequencing of the PCR products 
revealed a 253 bp deletion removing 210 bp of exon 3 and 43 bp of intron 3 (Fig.4B). 
Interestingly, the patient‟s brother, who presented similar WS2 features, also carries the 
deletion (Fig.4B). However, it was not found in the parent‟s DNA, suggesting germline 
mosaicism. We analysed hair roots, buccal and uroepithelial cell samples of both parents by 
PCR amplification, and found the band specific to the deleted allele in the mother‟s 
uroepithelial cell sample, showing the existence of somatic mosaicism (Fig.4C and Table 4). 
The second deletion encompasses 1777 bp and removes the whole exon 4, 1112 bp of intron 
3 and 396 bp of intron 4 (Fig.4A and D, patient 5). The father‟s DNA was not available. 
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However analysis of the mother‟s DNA by QMF-PCR and PCR sequencing techniques 
revealed the deletion is maternally inherited, in agreement with the observation that the 
mother also presents with WS2 (Fig.4D and Table 4). 
The other three deletions included the whole SOX10 gene, as well as POLR2F and the 
upstream S4 sequence (Fig.4A, patients 6, 7 and 8). Additionally, sequences S1 to S3 were 
deleted in patients 7 and 8. FISH analysis using the BAC clone RP5-1039K5 confirmed the 
presence of a deletion encompassing the whole region analysed in patient 8 (Fig.4A and E). 
Analysis of parents‟ samples revealed the de novo occurrence of the deletions in these three 
patients (Table 4). 
Molecular characterization of large deletions in patients presenting with WS2 
To define the boundaries of the 3 deletions encompassing the whole SOX10 gene we 
extended our analyses to adjacent regions. In the absence of material to perform FISH 
experiments in patients 6 and 7, we determined the boundaries of the deletion by repeating 
many sets of multiplex QMF-PCR (Fig.5B and data not shown). In the case of patient 6, 
additional sets of QMF-PCR primers between upstream S3 and S4 sequences allowed us to 
map the telomeric border of the deletion to a region located 20 to 21 kb upstream to the 
SOX10 start codon. The centromeric border was localized between genes CACNG2 and 
MYH9, therefore delimitating a deletion of 1.3 to 1.6 Mb that removes at least 42 genes 
including SOX10 and TRIOBP (Fig.5B). 
Patient 7‟s deletion removes 574 to 898 kb. Indeed, boundaries were located between 
LGALS2 and SH3BP on one side and C22ORF5 and KDELR3 on the other side. The deletion 
therefore encompasses 23 genes among which SOX10, TRIOBP and PLA2G6 (Fig.5B). 
In the case of patient 8, FISH analysis was performed using several probes including CTA-
415G2, LL22NC01-95B1, RP1-288L1, CTA-714B7, RP5-1177I5, RP1-37E16, CTA-228A9, 
RP1-5O6, RP3-434P1, CTA-150C2, RP4-742C19. The telomeric border was localized within 
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the RP4-742C19 BAC (we observed a significantly decreased signal on one of the 
chromosomes 22 in all the metaphases, Fig.5A) and the last centromeric deleted BACs was 
LL22NCO1-95B1 (Fig.5B and data not shown). QMF- PCR using primers within some of the 
genes located in the region confirmed the results, therefore delimiting a deletion of 5.5 to 6.1 
Mb encompassing 102 different genes including SOX10, LARGE , RASD2, RBM9, MYH9, 
CACNG2, TRIOBP, PLA2G6, KCNJ4, and NPTXR (Fig.5B and data not shown). 
The identification of five SOX10 deletions in 30 cases studied revealed that SOX10 is a new 
gene of WS2, and thus prompted us to screen for SOX10 point mutations. However, we failed 
to detect any mutation by DNA sequencing of the three SOX10 coding exons. Taken together, 
these results make SOX10 the third gene involved in WS2 with an estimated frequency (15%) 
similar to that of MITF. 
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Discussion 
Considering our panel of patients presenting with WS4 (classic forms of WS4 and PCWH), 
we estimated that for 20-30 % of them the phenotype is due to EDN3 or EDNRB point 
mutations, and for 40-50 % to SOX10 point mutations. In WS2 patients, mutations in the 
MITF gene were identified in about 15% of cases. Thus, 20-40% of WS4 and 85% of WS2 
cases remained unexplained at the molecular level, raising the possibility that other genes are 
involved, or that some mutations within the known genes are not detected by the methods 
commonly used for genotyping. In this study, we describe the first characterization of SOX10 
deletions in patients presenting with WS4 and WS2. We found 3 deletions among 30 WS4 
cases. Taking into account the fact that we only tested DNAs of patients negative for 
SOX10/EDN3/EDNRB point mutations, we estimate that SOX10 deletions are involved in 
about 5 % of all WS4 patients. We also found 5 deletions among 30 WS2 cases. As we only 
tested patients negative for MITF mutations, we can estimate that SOX10 deletions accounts 
for approximately 15% of all WS2 cases. These results extend the spectrum of SOX10 
mutations found in WS4 patients, and make SOX10 the third gene involved in WS2 with an 
estimated frequency similar to that of MITF. In terms of molecular diagnosis, SOX10 
deletions should now be searched for when no SOX10 point mutations (PCWH), or no 
SOX10, EDN3 and EDNRB point mutations (classical form of WS4), are found. More 
importantly, SOX10 deletions should be considered as a first step analysis in WS2, as well as 
MITF mutations. 
Full characterization of the 8 deletions by PCR and sequencing, or a combination of QMF-
PCR and fluorescent in situ hybridization (FISH), revealed 8 different deletion events ranging 
from the deletion of a single exon of SOX10 to that of up to 6 Mb around the SOX10 locus 
(Table 4). Both intragenic and full SOX10 deletions were observed either in WS2 or WS4. 
Intragenic deletions involved different exons. The observation of sequences surrounding the 
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breakpoints of the 3 intragenic deletions revealed no clear mechanism except for patient 5, 
where the deletion occurred between two hexanucleotide repeats „tggtgg‟, retaining one copy. 
Bioinformatic analysis using the Netgene2 and HMMgene software was performed to predict 
the functional consequences of these deletions. In case of patient 1, the rearrangement was 
predicted to activate a cryptic splice acceptor site within exon 5, located downstream the stop 
codon (780 nucleotides after the usual acceptor site, estimate frequency of 97%). The 
predicted protein would lack the last 206 amino acids, replaced by 27 unrelated amino acids, 
thereby removing the transactivation domain. In case of patient 4, the deletion removed the 
exon 3-intron 3 boundary. In silico analysis revealed that this deletion could result in 
translation of a short intronic sequence with a nearly immediate stop codon (5 amino acids 
downstream), the resulting protein being devoid of all functional domains. Alternatively, the 
use of a cryptic splice donor site (estimated frequency 55% or 88% depending on the 
program used), located 55 nucleotides downstream the missing donor site, could produce a 
protein lacking 69 amino acids, removing the dimerization domain and half of the HMG 
domain but leaving the transactivation domain intact. In case of patient 5, the Netgene2 
software predicted that the deletion could lead to exon 4 skipping, therefore resulting in a 
frameshift and a truncated protein of 189 amino acids with 47 unrelated amino acids in the 
carboxyterminal part. Half of the HMG domain and the following domains would be 
removed. Unfortunately, there is no SOX10-expressing tissue easily accessible by non 
invasive methods in patients, precluding analysis of the protein produced in vivo. 
Most of the SOX10 disease-associated point mutations identified so far, regardless of whether 
they cause WS4 or PCWH, result in premature termination codons (PTCs). An explanation 
for the presence or absence of a neurological phenotype (ie, central or peripheral) that 
characterizes the PCWH syndrome has been hypothesized to be related to non-sense mRNA 
decay (NMD) process 
57
. Truncating mutations located in the first coding exons (exons 3 and 
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4) activate the NMD RNA surveillance pathway, leading to haploinsufficiency and classic 
forms of WS4. On the other hand, truncating mutations located in the last coding exon (exon 
5) escape non-sense mRNA decay, leading to translation of an abnormal SOX10 protein with 
a dominant negative effect, therefore resulting in the more severe PCWH phenotype. 
Considering the published SOX10 point mutations 
18; 47; 49; 50; 52-58
 and our unpublished cases, 
we observed that the length of intestinal aganglionosis may also fit the NMD hypothesis, as 
all the point mutations associated with the long segment HSCR are located in the fifth exon. 
Accordingly, full deletions of SOX10 would be expected to cause classic forms of WS4 with 
short segment HSCR as a result of haploinsufficiency. All three patients indeed present with 
a short form, however two of them have a mild PCWH syndrome, an observation that does 
not match the non-sense mRNA decay hypothesis (Table 4). 
We wondered whether the PCWH syndrome may also result from other mechanisms, at least 
in some of the patients. Interestingly, one of the PCWH patients with a SOX10 deletion 
(patient 3) also carries a SOX10 valine to leucine substitution at the hemizygous state. This 
variation, which could worsen the phenotype of the patient, is located in a highly conserved 
region crucial to mediate DNA-dependent dimerization. We thus reasoned that the 
p.Val92Leu variation, although not a drastic substitution, might interfere with the formation 
of SOX10 dimers and thus specifically hamper promoter activation via natural target sites 
that require binding of SOX10 dimers. We therefore compared wild type and p.Val92Leu 
SOX10 transactivation capacities on MITF and GJB1 (Cx32) promoters, containing 
monomeric or dimeric binding sites, respectively, and found no differences. These results 
suggest that the p.Val92Leu variation does not affect SOX10 function at least in vitro, 
arguing in favor of the deletion as the major or sole cause of the PCWH phenotype observed. 
A contiguous gene syndrome may also account for the neurological features. The deletion 
identified in patient 3 encompasses the PLA2G6 gene known to be involved in a recessive 
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neurological defect (infantile neuroaxonal dystrophy 1, INAD1; neurodegeneration with brain 
iron accumulation; Karak syndrome) 
69
. However, this gene is not deleted in patient 2 who 
has a mild PCWH syndrome resembling that of patient 3, suggesting that the heterozygous 
PLA2G6 deletion is not involved in the phenotypic expression of the disease. 
In WS2 as in WS4, the largest deletions are found in patients presenting with additional 
symptoms, suggesting that some features may be influenced by the presence of other genes. 
Indeed, several genes removed by one or more of the deletions have a well-established 
neurological role (LARGE, RASD2, RBM9, CACNG2, KCNJ4, NPTXR). Two genes involved 
in human hearing loss are also located within some of the deleted regions: TRIOBP (recessive 
non-syndromic deafness DFNB28 
70
) and MYH9 (Epstein and Fechtner syndromes, dominant 
progressive isolated deafness DFNA17 
71; 72
). However, when comparing all 8 patients, we 
observed no clear correlation between the deletion of one of these genes, and the presence of 
neurological features or the deafness phenotype. In fact, as for SOX10 point mutations, 
SOX10 deletions by themselves might be sufficient to explain the phenotypes observed. On 
the other hand, the autism of patient 7, and the cardiac defects of patient 8, have not 
previously been linked to SOX10 mutations and may result from the deletion of additional 
genes. We found no evidence of a known gene removed by patient 8‟s deletion, which could 
explain the cardiopathy, but this deletion encompasses 102 genes and they are not all 
functionally characterized. In autism, recurrent deletions of chromosome 22q13 have been 
characterized 
73
, including a frequent breakpoint within the SHANK3 gene 
74
. However, this 
region is distal to the deletion found in patient 7. The question as to whether the association 
with autism in patient 7 is fortuitous or results from the deletion remains open. 
The Waardenburg syndrome subtypes were initially clinically defined. It appears however 
that this classification does not reflect the molecular mechanisms. Indeed, an overlap between 
WS1 and WS3 has already been reported, and we now report an overlap between WS2 and 
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WS4. In developmental syndromes, incomplete penetrance of some features is commonly 
observed. Incomplete penetrance of Hirschsprung disease is described both in isolated and in 
syndromic forms of the disease and it may result from different mechanisms, including 
genetic modifiers 
75; 76
. In the case of Waardenburg syndrome, incomplete penetrance of 
Hirschsprung disease could explain the overlap between WS2 and WS4. However, with 
regard to this hypothesis, it is surprising not to find SOX10 point mutations in WS2. To our 
knowledge, no genetic disorder has been described to result exclusively from deletions of the 
causative gene. It is possible that the penetrance of one feature varies between deletions and 
truncating point mutations, as shown for example in Von Hippel-Lindau disease 
77
. In our 
case, incomplete phenotypic penetrance may be explained by tissue-specific compensation of 
the loss of SOX10 by other SOX proteins having partly redundant function, such as SOX8 
and SOX9. Interestingly, in mice that expressed SOX8 instead of SOX10, the enteric defect 
was partially or totally rescued in homozygotes or heterozygotes, respectively, while the 
pigmentation defect was not 
78
. As a result, SOX10 haploinsufficiency may be compensated 
by SOX8/9 during enteric nervous system development, explaining the low penetrance of 
Hirschsprung disease associated to SOX10 deletions (leading to WS2 or WS4). In contrast, 
the presence of a truncated SOX10 protein may impair SOX8/9 function, resulting in a fully 
penetrant enteric phenotype (leading to WS4 only). However, it is possible that screening 
larger numbers of WS2 patients will result in the identification of SOX10 point mutations. 
An increasing diversity of clinical features is reported in Waardenburg syndrome: some WS4 
patients present with pseudoobstruction instead of Hirschsprung disease, and other with 
myelination defects of the peripheral and central nervous system, i.e. PCWH syndrome. In 
this study, patients 7 and 8 presented with WS2 and central and peripheral neurological 
features typical of PCWH – formally a new syndrome, indicating a continuum from isolated 
WS2 to severe PCWH. Based on our observation of SOX10 deletions in WS2, it appears 
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possible that EDN3 and EDNRB mutations also play a role in WS2. Indeed, in a subset of 
WS4 families with EDN3 or EDNRB point mutations, heterozygous relatives present with a 
diversity of features that may occasionally recalls WS2. It therefore appears necessary to 
undertake a more complete molecular analysis (point mutations, but also deletions) of all the 
genes involved in WS2 or WS4 (MITF, EDN3, EDNRB). These comprehensive studies are 
necessary to fully document the molecular complexity and close relationship that link the 
different subtypes of Waardenburg syndrome, and to reappraise their current clinical 
classification. 
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Table 1 
 Primer sequence (5’3’)    
Primer Forward Reverse reaction 
mix 
PCR 
size 
Gene-position 
NC 
Reference genes     
DSCR1 GCGACGAGGACGCATTCCAA GTCCTTGTGCGATCACCACA 1 and 2 238 DSCR1-exon4 
NC_000021.7 
F9 AAATGATGCTGTTACTGTCTA GAAGTTTCAGATACAGATTTTC 1 and 2 214 F9-exon5  
NC_000023.9 
SOX10 gene     
P5 GGCCAGGCGAGCTGGGCAAGGTC GAATCCACCCGAAGCTAGAG 1 341 SOX10-Exon3 
NC_000022.9 
P6 GGAGTGCTCTGGCATTCACG CTTGCCCCACCCTCAGCTCT 1 366 SOX10-Exon4 
NC_000022.9 
P7 GGAAGTTCACGTGCGCCCAC GCGGCAGGTACTGGTCCAAC 1 286 SOX10-Exon5 
NC_000022.9 
P8 CCACACTACACCGACCAGCC GGGTGGTGGCGACAGGGC 1 326 SOX10-Exon5 
NC_000022.9 
External markers     
P9 GATGACGTTTCTAGGTGG TGTTCCTAAGGATCTGTAGG 1 309 POLR2F-exon4 
NC_000022.9 
P1 GAGGAGGGAGTTTGGGTGGGTGG GCACAGGATGGGACGGGTTGAGA 2 310 -54694/-55003 
NC000022.9 
P2 TGGGAACAATGTCAACGTCG CAGAAGGCCTCCTCCAATGA 2 330 -32490/-32819 
NC000022.9 
P3 TACCAGGGCGGGCTCCTGTA GCCCCTGTTCCTTCCAGACTCCC 2 363 -14793/-15155 
NC000022.9 
P4 ACACGACGGCAGATGCTCGT CCTCGGAGCCCAGTGAATTA 2 335 -2116/-2450 
NC000022.9 
Table 1. Multiplex QMF-PCR primer sequences. GenBank, accession number (NC), 
position, sequences, expected PCR product size (bp) of primers P1 to P9. Position of primers 
P1 to P4 are indicated with the A of the SOX10 ATG numbered as 1. Homo sapiens Build 
36.2 was used. 
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Table 2  
 5’ SOX10 region  SOX10 gene  POLR2F gene 
 S4 (P4)  exon 3 (P5) exon 4 (P6) exon 5 (P7) exon 5 (P8)  exon 4 (P9) 
Subject 1 1.07  1.02 1.12 1.02 1.02  1.00 
Subject 2 1.02  1.08 1.03 0.97 0.93  0.94 
Patient 1 1.00  1.02 0.96 0.47 1.10  0.86 
Patient 2 0.46  0.50 0.46 0.51 0.49  0.45 
Patient 3 0.47  0.47 0.48 0.51 0.51  0.51 
Patient 4 1.20  0.58 0.90 1.17 1.20  0.83 
Patient 5 0.90  1.10 0.56 1.08 0.96  0.99 
Patient 6 0.52  0.54 0.48 0.52 0.56  0.43 
Patient 7 0.56  0.56 0.45 0.54 0.57  0.48 
Patient 8 0.51  0.46 0.53 0.50 0.49  0.50 
Table 2. DQ values from QMF-PCR performed with mix 1. The analysis is based on the 
comparison of the peak height from the tested DNA (two non deleted patients called subject 
1-2 and patients 1 to 8) and control DNA samples. The copy-number change for each 
amplicon was calculated using the peak value normalised to the peak value of the DSCR1 
gene exon 4. 
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Table 3 
Primer sequence (5’3’)  
Forward Reverse Gene-position and NC 
   
CGCCTCAGCTACCCCTCAGC CCGGCCCCAGCGTACCTGTA FBX07-exon1 NC_000022.9 
CTGGAGGGGTAGCAGTTAGC GATCGTTCAGATCCTTATAG TIMP3-exon1 NC_000022.9 
GATCAACAACTGTCAGCTCC CCTGCAGGTGGAGGCTGAGG ISX-exon1 NC_000022.9 
CGGTAGCAGCAATGGACTTT TCCTTACCTACTGGCTGTCA TOM1-exon1 NC_000022.9 
TTCAGGCATCTTCCTTGCAC AAGTCACTAACACTCAGCTC APOL3-exon4 NC_000022.9 
AGGCGGCTGTCTCCACCGGG GAGTGATTGTCTCAAAAGGC MYH9-intron1 NC_000022.9 
CACACTCTCCCGAGAACCAG CAAGTACCTTCTAGGCAGCA CACNG2-exon1 NC_000022.9 
GAGAGCCTGGCCTGGACACA GAAAGAGGACATGTTGAACC LGALS2-exon4 NC_000022.9 
TGTGACGGATGATTTCAGAT ATGCCCTCAGAAAGCAGCAT SH3BP1-exon10 NC_000022.9 
GGTGAAATTCCTCAGCTCTC GTATCTTACTTGTGCAAGGG TRIOBP-exon1 NC_000022.9 
CCCATGGATCACGCTGGTGC TAGGGGTGATGCCGTACCAG MICALL1-exon8 NC_000022.9 
TATAATGTACATGCTGCTGT GTACTGAGCCCAGGCAATCC MICALL1-intron9 NC_000022.9 
GACATCCATGGAGAGATGGA GAGCTCGGACTCTCGCCGCA MICALL1-exon11-12 NC_000022.9 
GGCAGCGGTGATTCAGCCCT ACTGAGATCCAAGGGCGCCT MICALL1-exon16 NC_000022.9 
GATGCTTTGCCCCTACAGTG GCTGAGGCTCAAGAGCATTG C22ORF23-exon4 NC_000022.9 
CAGAGGGCAGAAATTTTATT CATGATGTCCATGATGTGGC C22ORF23-exon3 NC_000022.9 
CAGTCAGCGCATGCGCACTT CAGACATTGCCCCTAGACGC POLR2F-exon1 NC_000022.9 
CAGAGGTAATCAAGTTAGCC GTATTAGGATGGGTCGTAGG P2_3-4 -20540/-20829 NC_000022.9 
CACCTGGCCAGGATGAGCTT CCACAGTGAGCACTCAGGAA P2_3-3 -21390/-21739 NC_000022.9 
TTGTAAAGCAACAGAGGAGC CCTTCCGCAAAGACTTGCTG P2_3-2 -23920/-24166 NC_000022.9 
CCAAAAGCAGAAATCTGGGA GGCCTGAGGCTCCAGCTGAG P2_3-1 -31482/-31759 NC_000022.9 
GATGGGATGGGAGGCAGTCT CCGTGGGTCAGCAGCACTAT PLA2G6-exon7 NC_000022.9 
GGCGGGAATGCTCTTGAGCT CACCCTGGACAGCATAATGG PLA2G6-exon4 NC_000022.9 
GGCTTCAGGAGGGCAGAGCA CCAGGGCTTTTAACATACCA PLA2G6-intron2 NC_000022.9 
CCTTCAGTGGCGTCACCAAC GGTCCAAGAGTACAGTCTCC PLA2G6-exon2 NC_000022.9 
CTCTAGACCTGGGGCCTCCG ATGCAGGCCTCTGCCACGAG C22ORF5-exon9 NC_000022.9 
TGGACCATGAACGTGTTCCG ATCATCTCGAGGGGTCCTCC KDELR3-exon1 NC_000022.9 
TTGTGCAGTCGCTGGGAAGG GATAGAGATCTGGGAGCGGG DDX17-exon1 NC_000022.9 
TCCTACCCCATCTGCCTTCT CCTGGAGCCTCCCAAAGGGC CBX7-intron1 NC_000022.9 
AGCCTGTGGCTTGGAGTGGC GTGGGAGCTCAGATCCCACC PDGFB-exon7 NC_000022.9 
Table 3. Additional QMF-PCR primers, ordered centromeric to telomeric. Position of primers 
P2_3-1 to 4 located between P2 and P3 (see table1) are given with the A of the SOX10 ATG 
numbered as 1. Homo sapiens Build 36.2 was used. NC: accession number 
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Table 4 
Table 4. Summary of clinical findings. The deletions are described in relation to the human genome 
reference sequence NCBI Built36.2 NT_011520.11. N°: number;B: brother; y: years; m:months; 
Pig.Ano: pigmentation anomalies; hypo-pig: hypopigmentation; MR: mental retardation; Del.: 
deletion. 
Patient 
 
Phenotype 
 
Molecular defect 
N° Gender Age 
 
WS 
type 
Deafness Pig.Ano. HSCR M R Others 
 
Inheritance Del. nomenclature Del. size 
              
1 M 1y 
 
WS4 Bilateral Hair and skin Short No Bilateral 
cryptorchidism 
 
De novo c.697-740_1085delins 
CCT 
1128pb
+ ins3bp 
              
2 M 13y 
 
PCWH Profound 
bilateral 
Hair and skin, 
sapphire blue 
eyes 
Short Mild Anosmia, 
hypermetropia, 
dental enamal 
abnormalities 
 
De novo g.(17,738,296_17,740,
110)_(17,794,727_17,
801,789) del (NCBI 
Build 36.2) 
56 to   
68 kb 
              
3 M 36y 
 
PCWH Profound 
bilateral 
Hair and skin, 
sapphire blue 
eyes 
Short Mild Anosmia, 
cryptorchidism 
hypogonadism 
 
De novo g.(17,712,505_17,716,
229)_(17,929,647_17,
933,832) del (NCBI 
Build 36.2) 
213 to     
222 kb 
              
4& 
B 
M 9y 
 
WS2 Profound 
bilateral 
Skin, irides 
and retinal 
hypo-pig. 
No No  
 
Maternal 
(mosaicism) 
c.219_428+43del 253 bp 
              
5 M 8y 
 
WS2 Profound 
bilateral 
Skin, 
hypoplastic 
irides 
No No  
 
Maternal c.429-
1112_697+396del 
1777 bp 
              
6 M 8y 
 
WS2 Profound 
bilateral 
White frontal 
forelock, 
heterochromia 
irides 
No No  
 
De novo g.(16,173,196_16,489,
188)_(17,790,847_17,
791,697) del (NCBI 
Build 36.2) 
1.3 to       
1.6 Mb 
              
7 M 23y 
 
WS2 Bilateral Skin, saphire 
blue eyes 
No Severe Short stature, 
pectus 
excavatum, 
autism 
 
De novo g.(17,357,039_17,432,
022)_(18,006,412_18,
254,748) del (NCBI 
Build 36.2) 
574 to     
898 kp 
              
8 F 19m 
 
WS2 Yes Skin, white 
forelock 
No Delayed Thumb 
duplication, 
congenital 
heart disease 
 
De novo g.(Z83846_Z69042)_ 
(18,938,054_19,010,3
79)del (NCBI Build 
36.2) 
5.5 to       
6.1 Mb 
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Figure legends: 
Figure 1: SOX10 deletions in patients presenting with classical form of WS4 or PCWH. 
(A) Schematic representation of the 3 deletions identified by QMF-PCR. Scheme on the top 
indicates the SOX10 gene structure (an approximate scale is shown on the right). SOX10 
coding sequence (exons 3 to 5) is indicated with black boxes, and non coding exonic 
sequence with white boxes. Arrowheads indicate the position of the segments analysed by 
multiplex QMF-PCR (P1 to P9; see table 1 for corresponding primers sequences). They 
include the downstream adjacent POLR2F gene (grey box) and 4 short regions located up to 
50kb upstream of SOX10, indicated by dark lines and called S1 to S4. QMF-PCR results of 
patients 1 to 3 are indicated below: „+‟ = not deleted or „-‟ = deleted. The phenotypes are 
indicated on the left. (B) Schematic representation (top) and electropherogram (bottom) of 
the deletion breakpoint region of patient 1. The size of the deletion and the nucleotidic 
localisation of the breakpoint are indicated on the diagram. The 3 inserted nucleotides are 
boxed. (C) Hybridization pattern of patients 2 and 3 using the BAC clone RP5-1039K5 
encompassing the SOX10 locus (indicated on the top of scheme A). The BAC clone RP5-
1039K5 is labelled in red and the control probe in green (RP1-41P2). The normal 
chromosome 22 is indicated by an arrow and the deleted chromosome 22 by an arrowhead. 
Figure 2: Functional consequences of the p.Val92Leu (V92L) mutation. (A) Amino acid 
sequence comparison of the region immediately preceding the HMG domain of SOX10 
proteins across evolution and of SOX subgroup E proteins (human sequences). Gaps are 
indicated by blanks. The first part of HMG domain is boxed, and the amino acid substitution 
V92L from patient 3 is indicated by an arrow. SOX10 sequence references: human (accession 
number NP_008872.1); mouse (XP_128139.4); chicken (NP_990123.1); fugu 
(NP_001072112.1); zebrafish (NP_571950.1); human SOX8 (NP_055402.2) and human 
SOX9 (NP_000337.1). (B) Subcellular localization of wild-type SOX10 and p.Val92Leu 
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mutant: HeLa cells were transfected with pECE-SOX10 (WT) or mutant (V92L) constructs 
for 24h, fixed and immunostained for SOX10. Cultures were counterstained with Dapi. (C 
and D) Transactivation capacities of SOX10 proteins. The MITF promoter (pMITF) (C) or 
the GJB1 (pCx32) (D) promoter luciferase reporters were transfected in Hela cells in 
combination with wild type (WT) or mutant SOX10 proteins (V92L; E189X; 482ins6; 
Y313X), and /or PAX3 (C) or EGR2 (D). Reporter gene activations are presented as fold 
induction relative to the empty expression vector (pECE). Results represent the mean ± SME 
from 6 experiments, each performed in duplicate. Insets in C, D show a schematic 
representation of relative localisation of SOX10 (white boxes), PAX3 (striped circles) or 
EGR2 (striped triangle) binding sites on MITF or GJB1 (Cx32) promoters. 
Figure 3: Determination of the extent of large deletions in PCWH patients. Schematic 
representation of the deletions in patients 2 and 3, determined by FISH (A) or QMF-PCR 
experiments (B). Representative FISH results are shown in (A). The names of the BACs used 
for hybridization are indicated on each panel. Scheme (B) indicates the names, positions and 
orientation of genes located proximal or distal of SOX10. An approximate scale is shown. 
BACs used for FISH experiments are shown on the left and segments analysed by multiplex 
QMF-PCR are indicated by arrowheads (see table 3 for corresponding primers sequences). 
QMF-PCR results of patients 2 and 3 are indicated next to the corresponding fragments: „+‟ = 
not deleted or „-‟ = deleted. 
Figure 4: SOX10 deletions in patients presenting with WS2. (A) Schematic representation 
of the 5 deletions identified by QMF-PCR. Scheme on the top indicates the SOX10 gene 
structure, QMF-PCR experiments results („+‟ = non deleted or „-‟ = deleted) as described in 
Figure 1. (B and D) Schematic representation (top) and electropherograms (bottom) of the 
breakpoint deletion region of patient 4 (B) and patient 5 (D) and their relatives. The size of 
the deletions and the breakpoints are indicated on the scheme. (C) PCR covering exons 3 and 
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intron-exons boundaries using patient 4, his brother, mother and father‟s DNAs extracted 
from leucocytes (L), buccal cells (B), uroepithelial cells (U) and hair roots (H). The normal 
band is indicated by an arrow and the mutant allele by an arrowhead. Note the faint mutant 
band in the mother‟s uroepithelial cells. (E) Representative FISH result obtained for patient 8 
with the probe RP5-1039K5 encompassing the SOX10 locus (indicated on the top of scheme 
A). The BAC clone RP5-1039K5 is labelled in red and the control probe (RP1-127L4) in 
green. The normal chromosome 22 is indicated by an arrow and the deleted chromosome 22 
by an arrowhead. 
Figure 5: Determination of the extent of large deletions in WS2. Schematic representation 
of the deletions in patients 6, 7 and 8, determined by FISH (A) or QMF-PCR experiments (B) 
as described in figure 3. Only the first not deleted or partially deleted BACs are shown in (A). 
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